The Non-infectious Uveitis drugs in development market research report provides comprehensive information on the therapeutics under development for Non-infectious Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Non-infectious Uveitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Non-infectious Uveitis and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Non-infectious Uveitis by 16 companies/universities/institutes. The top development phase for Non-infectious Uveitis is preclinical with five drugs in that stage. The Non-infectious Uveitis pipeline has 16 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Non-infectious Uveitis pipeline products market are: Avirmax, Ripple therapeutics and Acelyrin.
The key targets in the Non-infectious Uveitis pipeline products market include Tumor Necrosis Factor, Inosine Monophosphate Dehydrogenase, and Glucocorticoid Receptor.
The key mechanisms of action in the Non-infectious Uveitis pipeline product include Glucocorticoid Receptor Agonist with two drugs in Phase III. The Non-infectious Uveitis pipeline products include seven routes of administration with the top ROA being Intravitreal and seven key molecule types in the Non-infectious Uveitis pipeline products market including Small Molecule, and Synthetic Peptide.
Non-infectious Uveitis overview
Non-infectious uveitis (NIU) is a group of disorders characterized by intraocular inflammation at different levels of the eye. NIU is a leading cause of irreversible blindness in working-age population in the developed world. Noninfectious uveitis can result from an eye injury or a disease somewhere else in your body. The goal of uveitis treatment is to control inflammation, prevent recurrences, and preserve vision, as well as minimize the adverse effects of medications.
For a complete picture of Non-infectious Uveitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
